Set for release in 2026, the ‘first-of-its-kind’ technology aims to give researchers the ability to analyse more cells in a ...

Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...

Illumina announces a new NGS-based spatial technology kit and new software platform, Illumina Connected Multiomics.

RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

The DNA Sequencing Industry has rapidly transformed into one of the most crucial areas of biotechnology. What was once a time ...

Beijing’s surprise move to blacklist Illumina Inc. has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant.

Illumina is one of Mainboard-listed Venture Corporation’s major customers. Illumina’s shares have fallen some 26.4% over the ...

Details and early access customer data will be presented next week during Illumina's Gold Sponsor Workshop at the Advances in ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...